Ahmad Izuanuddin Ismail Malaysia

Prof. Dr. Ahmad Izuanuddin Ismail is a distinguished academic and consultant respiratory physician with a career spanning over two decades. He completed his medical degree from University College Dublin in 2002 and attained his MRCP in 2007. His expertise lies in respiratory and internal medicine, with subspecialty training completed in 2012. Currently, Prof. Izuan serves as a Professor of Medicine at Universiti Teknologi MARA (UiTM) and Director at Hospital Al Sultan Abdullah, UiTM. He is also a Visiting Consultant at KPJ Rawang Specialist Hospital. His leadership roles include past tenure as Medical Director at UiTM Private Specialist Centre and Deputy Dean of Clinical Services. An avid researcher, Prof. Izuan has published extensively in areas such as tuberculosis, COPD, asthma, and sleep-disordered breathing. He has been the principal investigator for numerous international clinical trials and recipient of multiple research grants. Beyond academia and clinical practice, Prof. Izuan is a sought-after speaker, delivering presentations on national and international platforms. His work has earned him recognition and awards, underscoring his contributions to advancing thoracic and respiratory medicine globally. Prof Izuan is the current President of Malaysian Thoracic Society (MTS), Sleep Disorder Society Malaysia (SDSM), and APSR 2026 Congress
Job Title
Professor of Medicine & Director
Faculty / Department / Division
Faculty of Medicine, Universiti Teknologi MARA
Institution / Organisation
Hospital Al-Sultan Abdullah, Universiti Teknologi MARA

19 November 2026, Thursday

Time Session
08:30
13:00
Naricha Chirakalwasan Chairperson Thailand
Rashidah Yasin Chairperson Malaysia
Function Room 8, Ground Mezzanine Floor

20 November 2026, Friday

Time Session
08:00
08:30
APSR’s Leadership in Advancing Respiratory Medicine and Sciences in Asia
Yoshinori Hasegawa Speaker Japan
Ahmad Izuanuddin Ismail Chairperson Malaysia
Established in 1986 to advance respiratory medicine and combat respiratory diseases in the Asia-Pacific, the Asian Pacific Society of Respirology (APSR) has grown into a major international society and a Founding Member of the Forum of International Respiratory Societies (FIRS). The APSR’s mission is to advance and disseminate knowledge of the respiratory system in health and disease across the Asia-Pacific and globally, aiming to bridge regional healthcare disparities and elevate research, education, and clinical practice. Guided by its vision to reshape the future of respiratory medicine through innovative, patient-centered, equitable, and sustainable care, the Society promotes collaboration among researchers and clinicians to provide optimal respiratory care tailored to the region’s diverse healthcare infrastructures and disease burdens. This lecture reviews the past year's achievements and key initiatives across five core pillars: hosting the annual APSR Congress, publishing official journals (Respirology and Respirology Case Reports), nurturing early-career researchers through education and fellowships, leading Assembly and Section activities, and advancing global advocacy and international partnerships. A defining feature of the APSR is its "en bloc" society membership system. By integrating national respiratory societies, this strategy driven rapid expansion, rendering the APSR the largest respiratory society in the region. This sheer scale grants the Society strong leverage in international negotiations and policy advocacy alongside global bodies such as the WHO, ATS, and ERS. The en bloc membership system has expanded the APSR's reach and strengthened collaboration among respiratory societies across the Asia-Pacific. Building on this foundation, the APSR aims to encourage greater individual member participation and raise awareness of benefits such as journal access, educational programs, and fellowships. Closer partnerships with national and regional societies, together with clearer communication of the APSR's achievements, will further strengthen members' sense of connection and shared purpose. These efforts will enhance membership value and support the Society's sustainable growth.
Ballroom 3, Lower Ground Floor
08:30
09:00
Mycobacterial Genomics: Potential for Pulmonary NTM Disease Management
Toshiaki Kikuchi Speaker Japan
Ahmad Izuanuddin Ismail Chairperson Malaysia
Mycobacterial Genomics: Potential for Pulmonary NTM Disease Management Toshiaki Kikuchi, MD, PhD Niigata University Medical & Dental Hospital, Japan Background and Aims The incidence of pulmonary nontuberculous mycobacterial (NTM) disease is increasing worldwide, particularly in Japan, where Mycobacterium avium complex predominates. Some patients experience disease progression that requires antimicrobial treatment, whereas others remain stable without treatment for years. Because disease progression is difficult to predict, deciding when to start treatment remains challenging. We investigated whether the genomic characteristics of M. avium clinical isolates are associated with disease progression. Methods We performed whole-genome sequencing of 36 clinical M. avium isolates from patients with progressive (n = 25) or stable (n = 11) disease. Progressive disease was defined as initiation of treatment within 12 months of diagnosis, and stable disease as no treatment during this period. Comparative analyses included whole-genome alignment, phylogenetic analysis based on average amino acid identity (AAI), and single-nucleotide variant (SNV) analysis. Results Comparative genomic analysis identified a 1.4-Mb genomic inversion that distinguished two genomic types, type A and type non-A. All 15 type A isolates were from patients with progressive disease, whereas the 21 type non-A isolates were from patients with progressive (n = 10) or stable (n = 11) disease. Type A isolates also lacked genes adjacent to the inversion breakpoints, including the vapBC-5 toxin–antitoxin system, which may affect the regulation of bacterial growth. AAI-based phylogenetic analysis independently separated type A from type non-A isolates and revealed additional clusters associated with disease progression. Furthermore, SNV analysis of type non-A isolates identified variants associated with progression, including one in uvrB, a gene involved in DNA repair. Conclusion These findings suggest that genomic profiling of M. avium isolates may help predict disease progression and guide individualized treatment decisions in pulmonary NTM disease. Keywords: Nontuberculous mycobacteria, Whole-genome sequencing, Disease progression Reference: Tanaka K et al, Int J Infect Dis, 2026, 169, 108816. Disclosure Statement: The presenting author has received honoraria or consultation fees from Insmed, KYORIN Pharmaceutical, and Janssen Pharmaceutical.
Ballroom 3, Lower Ground Floor
09:30
11:00
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
  • David Halpin Speaker United Kingdom
  • Antonio Anzueto Speaker United States
  • Wisia Wedzicha Speaker United Kingdom
    This presentation will review aspects of COPD exacerbation management in the GOLD 2027 report.
  • Pang Yong Kek Speaker Malaysia
    Title: Leveraging Digital Tools in COPD Management for 2027 & Beyond Routine outpatient management of COPD faces a double deficit: up to 70% of patients make critical inhaler errors, with real-world adherence below 50%, whilst fewer than 3% complete centre-based pulmonary rehabilitation (PR). Digital healthcare addresses this through two synergistic pillars: connected smart inhalers—which enhance adherence by 22%–35% and reduce exacerbations by 17%–30% via objective flow and technique tracking—and digital therapeutics like myCOPD and Kaia COPD, which improve exercise capacity (+57.68 m 6MWD) with outcomes non-inferior to in-person PR. Remote Therapeutic Monitoring (RTM) billing frameworks establish clinical and financial viability by reimbursing multidisciplinary management of non-physiological data, medication adherence, and patient-reported outcomes. Looking toward 2027, multi-modal data fusion—integrating wearable vitals, acoustic cough biomarkers, and smart inhaler actuations—enables machine learning algorithms to forecast acute exacerbations up to 7 days ahead with 92% accuracy, aligning with recent GOLD strategy updates on early phenotypes (Pre-COPD/PRISm) and AI integration. Crucially, digital tools fail in isolation: patient engagement drops to 20% without supervision but exceeds 85% within a structured "clinician-in-the-loop" model, proving human clinical oversight remains essential for successful digital transformation.
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
    Pang Yong Kek Chairperson Malaysia
Ballroom 1, Lower Ground Floor
12:00
13:00
Sponsored by GlaxoSmithKline
Ahmad Izuanuddin Ismail Chairperson Malaysia
Ballroom 2, Lower Ground Floor
14:00
15:00
Brendon Yee Chairperson Australia
Rozanah Abdul Rahman Chairperson Malaysia
  • Ahmad Izuanuddin Ismail Speaker Malaysia
    "Obesity and obstructive sleep apnoea (OSA) are often approached as separate clinical problems: obesity as excess weight and OSA as upper-airway obstruction. This conventional framework, however, fails to capture the complex bidirectional relationship between adiposity, sleep-disordered breathing and cardiometabolic disease. Obesity is a chronic, relapsing disease characterised by dysfunctional adipose tissue, visceral and ectopic fat accumulation, inflammation, insulin resistance and altered neuroendocrine signalling. These processes can substantially influence respiratory mechanics, upper-airway collapsibility and ventilatory control, contributing to the development and progression of OSA. Conversely, untreated OSA produces recurrent intermittent hypoxia, sleep fragmentation and sympathetic activation, promoting oxidative stress, endothelial dysfunction, hypertension, insulin resistance and broader cardiometabolic consequences. The interaction between obesity and OSA therefore creates a self-reinforcing cycle that extends far beyond the airway. This presentation explores the pathophysiological continuum linking obesity, OSA and cardiometabolic disease, and considers its implications for public health. Traditional treatment strategies, including lifestyle intervention, positive airway pressure and metabolic/bariatric surgery, remain fundamental. However, emerging pharmacological therapies offer an opportunity to address upstream biological drivers of disease. In particular, GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists represent an important evolution in obesity management, with emerging evidence demonstrating improvements in OSA severity and cardiometabolic risk alongside substantial weight reduction. The future of sleep medicine may therefore lie beyond treating airway obstruction alone. A personalised, integrated approach—combining airway therapy, obesity treatment, lifestyle intervention and cardiometabolic risk reduction—offers an opportunity to treat the patient rather than simply the apnoea. Obesity is more than a weight issue, and OSA is more than an airway problem. "
  • Yizhong Zheng Speaker Australia
    The Asia-Pacific now carries the world’s largest burden of obesity, yet obesity hypoventilation syndrome (OHS) remains under-recognised and often presents late, with acute respiratory failure. This talk examines whether current diagnostic criteria and screening tools, largely derived from non-Asian populations, serve our patients well. It explores why Asian patients may develop OHS at a lower BMI, how to identify them earlier, and how to choose and optimise PAP therapy. Finally, it considers where bariatric surgery and the new incretin-based therapies fit in a disease that PAP alone does not cure.
  • Brendon Yee Speaker Australia
    "Obstructive sleep apnoea (OSA) affects an estimated one billion adults worldwide, most of whom are overweight or obese. Yet care remains largely mechanical: diagnose, prescribe positive airway pressure (PAP), advise weight loss, and judge success by device-reported AHI. Weight-loss advice is rarely structured or followed up, and PAP, while controlling AHI and symptoms, has not been shown to alter cardiometabolic trajectory. This presentation argues for a shift in the sleep physician's role. Weight loss is disease-modifying: a 20% BMI reduction is associated with an approximately 57% fall in AHI, acting chiefly on pharyngeal collapsibility, the dominant OSA endotype. In SURMOUNT-OSA, tirzepatide reduced AHI by 20–24 events/h versus placebo over 52 weeks, with or without PAP, alongside improvements in hypoxic burden, sleepiness, blood pressure, hsCRP and patient-reported outcomes. Mediation analyses show these cardiometabolic benefits are driven predominantly by weight loss, with AHI and hypoxic-burden reduction independently mediating selected outcomes. Meta-analytic and real-world data support a class effect. A practical model of care is then outlined: patient selection, clinical and financial consent, monitoring for gastrointestinal effects, lean-mass loss and weight regain, and multidisciplinary co-management with primary care, dietetics, exercise physiology and psychology. Incretin therapy is positioned as complementary to PAP, not a replacement. Finally, Asia-Pacific realities are addressed, including variable approval and reimbursement, out-of-pocket costs, and growing cosmetic and grey-market GLP-1 use, underscoring why sleep physicians must own the medical narrative."
  • Q&A
Ballroom 3, Lower Ground Floor